Products

TGFK07AD
Therapeutic Area(s): Major Depression
Phase III - 1-2 Additional trials needed for NDA

Clinical Trials
2 Pivotal Trials in Depression of ER formulation.

The accumulated safety data for TGFK07AD is extensive. There have been 850 subjects entered in Phase I trials. In Phase II & III, 1900 patients have been treated with TGFK07AD Immediate Release and 3100 with TGFK07AD Extended Release. In addition, 634 children and adolescents were enrolled into pediatric trials in depression.

The extensive clinical experience with TGFK07AD has shown it free of troublesome adverse events. Common adverse events are limited to transient lightheadedness, nausea, and headache. Sexual dysfunction and weight gain, common problems with other antidepressants, are not found with treatment of TGFK07AD.

Partners
Developmental opportunities are available